[Research progress on penis cavernosa fibrosis].

Penis cavernosa fibrosis is an important cause of refractory erectile dysfunction.Its exact pathogenesis remains incompletely elucidated, and conventional treatment is not effective, seriously affecting the quality of life, physical and mental health of men. With the deepening of research, the progress of two-dimensional shear wave elastography (2D-SWE) and molecular imaging provides the possibility for the early diagnosis, grading and staging of cavernous fibrosis. Studies on stem cell therapy, energy-based treatments, targeted therapy, and traditional Chinese medicine show promising applications in the anti-penile cavernous fibrosis. This article reviews the research progress in the diagnosis and treatment of penile cavernosis fibrosis.

Peyronie's disease: what do we know and how do we treat it?

INTRODUCTION: Peyronie's disease is a common, benign condition characterized by an acquired penile abnormality due to fibrosis of the tunica albuginea. This may lead to penile curvature, deformity, discomfort, pain, and erectile dysfunction, resulting in emotional and psychosocial effects on patients. Therefore, it is important for urologists to thoroughly evaluate the extent of the patient's bother and discuss treatment goals, therapeutic options, and expectations. MATERIALS AND METHODS: We provide a review of the current landscape for the diagnosis, management, and treatment of Peyronie's disease, including oral, topical, intralesional, external energy, and surgical therapies. RESULTS: The hallmark of managing Peyronie's disease is attentive patient counseling. Patients may be hesitant to discuss their symptoms unless inquired directly and may not be aware that treatments exist. It is not uncommon for Peyronie's disease to be diagnosed incidentally during a routine or unrelated healthcare visit, with reported rates of incidental diagnosis as high as 16%. Treatment options are stratified by disease phase which is defined by whether symptoms (e.g. penile deformity and discomfort) are actively changing or have stabilized. Conservative therapy is the most common recommendation during the active phase with more invasive treatments reserved for the passive phase. Conservative therapy may include oral or topical medication, intralesional injection, and external energy therapy. These treatments may also have a role in improving symptoms during the passive phase prior to undergoing more definitive surgical treatment. Surgical interventions include tunical plication, plaque incision or excision with or without grafting, and penile prosthesis implantation. Despite the variety of treatment options available to patients, each has a distinct efficacy and adverse effect profile, warranting thorough discussion to meet patients' goals and manage expectations. CONCLUSION: Peyronie's disease is a common condition that is underdiagnosed and undertreated. Patients with Peyronie's disease will benefit from a comprehensive evaluation and in-depth counseling so that they may become familiar with the natural disease course and have appropriate expectations of each treatment option.

Does Transfer Capacitive Resistive Energy Has a Therapeutic Effect on Peyronie's Disease? Randomized, Single-Blind, Sham-Controlled Study on 96 Patients: Fast Pain Relief.

Background/Aims/Objectives: We have investigated the clinical and physiological effects of Transfer Capacitive Resistive Energy (TCARE) therapy on men with Peyronie's disease (PD). METHODS: Ninety-six men with PD have been randomized in a 2:1 ratio to receive 3 sessions of TCARE therapy or sham therapy. Pain, penile curvature and erectile function have been assessed before the first treatment and up to 9 months after the end of treatment, using the Visual Analogue Scale for the pain, a goniometer to measure the degree of curvature using at-home photography and an International Index of Erectile Function (IIEF-5) questionnaire. RESULTS: A significant pain reduction at the end of the treatment in 51 (79.6%) patients (p < 0.01) of the treated group was observed. No significant improvements in the sham group (p = 0.23) have been observed. No statistical differences in the degree of curvature have been observed in both groups. No statistical improvements have been observed in the IIEF-5 questionnaire. Adverse events have not been reported. CONCLUSION: This is, to our knowledge, the first randomized, single-blind, sham-controlled study that shows that TCARE has a positive short-term clinical effect on pain in patients with PD. The feasibility and tolerability of this treatment produce an attractive new therapeutic option for men with PD.

Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases.

The medical treatment is indicated in the development stage of Peyronie's disease (PD) for at least 1 year after diagnosis and whenever in case of penile pain. This research was conducted to demonstrate the possible effectiveness of vitamin E in PD treatment, whereas in the scientific literature this topic is much discussed. A total of 70 patients (age:26-69 years, mean: 54.1 ± 9.71) diagnosed with PD were enrolled in a conservative treatment. In addition to medical histories and physical examinations all patients underwent the following tests: International Index of Erectile Function (IIEF) questionnaire, penile ultrasound and photographic documentation, pain evaluation by a conventional 10-point pain scale Visual analogue pain scale (VAS). All 70 patients were divided into two different treatment groups: A and B, with different combinations of drugs: A = vitamin E + verapamil (injection + iontophoresis) + blueberries + propolis + topical diclofenac; B = verapamil (injection + iontophoresis) + blueberries + propolis + topical diclofenac. All patients were treated for 6 months after which they underwent the same follow-up tests as performed prior to the treatment. Intergroup analysis revealed statistically significant differences: in the vitamin E group the effective plaque size reduction was -50.2% whereas in the control group the reduction was -35.8% (p = 0.027). In group A the improvement of curvature occurred in 96.6% of the cases whereas in the control group B this occurred in 48.4% (p = 0.0001), moreover, the mean curvature decrease was respectively -12.25° and -6.73° (p = 0.01). IIEF score was significantly improved in group A patients with comorbidities and erectile dysfunction (p = 0.025). Increase in plaque size occurred only in the control group (17.1%) (p = 0.032). We can affirm that vitamin E can help to prevent the progression of PD. This study strongly supports the recommendation that the best approach for treating PD is multimodal therapy.

Propóleos, inmunología y enfermedad de Peyronie / Propolis, Immunology and Peyronie's disease

Introducción: En varias investigaciones anteriores publicadas, hemos demostrado mejoría clínica de la enfermedad de Peyronie (EP) con propóleos. De las propiedades del propóleos, la inmunoestabilizadora es la que, hipotéticamente, produce dichos efectos. Objetivos: Analizar y conocer la correlación de la EP, el propóleos, la inmunología y la mejoría clínica. Material y métodos: Estudio prospectivo, pareado, ensayo clínico. Se estudian 30 pacientes. Dosis de 900 mg de propóleos diario durante 6 meses. Variables estudiadas: edad, raza, dirección de la curvatura, dolor, tamaño de la placa (pre y postratamiento) medida por exploración física, ecografía y ángulo de curvatura, dosificaciones de IgA, IgG, IGm, C3, C4, factor reumatoideo, proteína C reactiva, pruebas cutáneas. Resultados: La edad no presentó un predominio significativo. En cambio respecto a la raza, el 70% eran blancos. La curvatura, predominantemente, fue hacia arriba (40%). Con dolor consultó el 53,3%, siendo más manifiesto en los que tenían una curvatura hacia arriba (8 de los 12 casos). La modificación promedio en el grado de angulación (pre vs. postratamiento) fue de 38,1 g (pretratamiento) vs. 29,5 g (postratamiento) (p < 0,001). La variación en el tamaño de la placa, expresada en medición promedio de cada una de las 3 dimensiones, fue: medición física (cm) (1,9 × 1,3 × 1,3 pretratamiento) vs. (1,5 × 1,1 × 1,1 postratamiento) (p < 0,008, p < 0,0003, p < 0,0003); medición ecográfica (mm) (12,6 × 7,8 × 11,4 pretratamiento) vs. (11,7 × 7,5 × 5,1 postratamiento), p < 0,005). Pruebas humorales inmunológicas: C3 bajo en la mayoría de los pacientes. C4 rango normal. Aumento de C3 postratamiento a niveles normales y en las restantes que tenían niveles normales, pero en rangos limítrofes normales inferiores, aumentaron postratamiento (IGg, IGm, IGa y C4): en la inmunidad celular pretratamiento, pacientes inmunodeprimidos 18, moderadamente deprimidos 2 y normales 10 (33,3%). Postratamiento, sólo 1 paciente inmunodeprimido. Discusión: Al evaluar las variables principales de la investigación, observamos que la angulación del pene después del tratamiento durante 6 meses con propóleos se redujo notablemente, así como el tamaño de la placa medida físicamente por el investigador, y ecográficamente por el imagenólogo, se redujo al finalizar el tratamiento. Y, finalmente, analizando el sistema inmunológico de los pacientes tratados antes y después del tratamiento, los que lo tenían deprimido en mayor o menor grado se normalizaron, y otros pacientes cuyas cifras en los test eran normales, pero en el límite inferior de los valores referenciales, aumentaron al finalizar el tratamiento. Conclusiones: Existe una relación de inmunología deprimida en pacientes afectos de EP. La mejoría clínica de estos pacientes con EP, tratados con propóleos, se asocia a la mejoría inmunológica. Con un tratamiento de propóleos, se reduce el ángulo de curvatura del pene, la placa disminuye su tamaño y mejora su estado inmunológico deficiente (AU)

Introduction: In several previously published articles, we have shown clinical improvement in Peyronie's disease (PD) with propolis. Among the properties of propolis, immunostabilization is that which hypothetically corresponds to these effects. Objectives: To analyze and determine the associations among PD, propolis, immunology and clinical improvement. Material and methods: We performed a prospective, paired clinical trial of 30 patients. A dose of 900 mg propolis daily was administered for 6 months. The variables studied were age, race, direction of the curvature, pain, size of the plaque (pre- and post-treatment), as measured by physical examination, ultrasound and angle of curvature; levels of IgA, IgG, IGm, C3, C4, rheumatoid factor and C-reactive protein, and the results of skin tests. Results: There was no predominant age, while 70% of the patients were white. The curvature was predominantly upwards (40%).Pain was present in 53.3%, and was more frequent when the curvature was upwards (8 of the 12 patients). The mean change in the degree of angulation (pre- vs. post- treatment) was 38.1º(pre-treatment) vs. 29.5º(post-treatment) (p < 0.001). The variation in the size of the plaque, expressed as the mean of each of the three dimensions was as follows: physical measurement (cm) (1.9×1.3×1.3 pre-treatment) vs. (1.5×1.1×1.1 post-treatment) (p<0.008, p<0.0003, p<0.0003); ultrasound measurement (mm) (12.6x7.8×11.4(pre-treatment) vs. (11.7×7.5×5.1 post-treatment) (p < 0.005). The results of humoral immunological tests were as follows: C3 levels were low in the majority of the patients; C4 levels were within the normal range; C3 concentrations increased after treatment to within the normal range and levels increased after treatment in the remaining patients who had levels at the lower limit of normal before treatment. The results of cellular immunity tests (IGg, IGm, IGa and C4) showed that before treatment 18 patients were immunodepressed, two showed moderate immunodepression and 10 showed normal cellular immune function (33.3%). After treatment, only one patient was immunodepressed. Discussion: On evaluating the main variables, we found that the angle of the penis after 6 months of treatment with propolis was significantly reduced. The size of the plaque measured physically by the physician and sonographically by the sonographer was also reduced at the end of the treatment. In patients who were immunodepressed before treatment, immune function returned to normal to a greater or lesser extent. Patients with low values before treatment showed improved immune function after treatment. Conclusions: There is an association between immunodepression and PD. The clinical improvement in patients with PD treated with propolis was associated with improved immune function. Propolis reduces the angle of penile curvature and the size of the plaque and improves immune function (AU)